A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo

Molecular Pharmacology

Volumn 53, Issue 6, 1998, Pages 999-1008

  Gardner, Iain ^a   Leeder, J Steven ^c   Chin, Terrence ^a   Zahid, Nasir ^a   Uetrecht, Jack P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DRUG METABOLITE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; OLANZAPINE;

AGRANULOCYTOSIS; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DEGRADATION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BONE MARROW; CLOZAPINE; FEMALE; HUMANS; HYPOCHLOROUS ACID; IMMUNE SERA; IMMUNOBLOTTING; MALE; NEUTROPHILS; PEROXIDASE; PIRENZEPINE; RABBITS; RATS; RATS, INBRED LEW;

EID: 0031814439     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alvir JJ, Lieberman JA, Safferman AZ, Schwimmer JL, and Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329:162-167.
2. Andrews PC and Krinski NI (1981) The reductive cleavage of myeloperoxidase in half, producing enzymically active hemi-myeloperoxidase. J Biol Chem 256:411-418.
3. Aravagiri M, Ames D, Wirshing WC, and Marder SR (1997) Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 19:307-313.
4. Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, and Yunis EJ (1995) The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86:3835-3840.
5. Edwards SW (1994) Biochemistry and Physiology of the Neutrophil, Cambridge University Press, New York.
6. Fulton B and Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298.
7. Furusawa S, Ohashi Y, and Asanoi H (1996) Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. J Clin Pharmacol 36:477-481.
8. Gardner I, Zahid N, MacCrimmon D, and Uetrecht JP (1998) A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 53:991-998.
9. Gut J, Christen U, and Huwyler J (1993) Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 58:133-155.
10. Hellewell PG and Williams TJ (1994) The neutrophil, in Immunopharmacology of neutrophils (Hellewell PG and Williams TJ, eds) pp 1-3, Academic Press, San Diego, CA.
11. Jaunkalns R, Shear NH, Sokoluk B, Gardner D, Claas F, and Uetrecht JP (1992) Anti-myeloperoxidase antibodies and adverse reactions to clozapine. Lancet 339: 1611-1612.
12. Kenna JG and Neuberger JM (1995) Immunopathogenesis and treatment of halothane hepatitis. Clin Immunother 3:108-124.
13. Kenna JG, Satoh H, Christ DD, and Pohl LR (1988) Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 245:1103-1109.
14. Klebanoff SJ (1990) Myeloperoxidase: occurrence and biological function, in Peroxidases in Chemistry and Biology (Everse J, Everse KE, and Grisham MB, eds) pp 1-36, CRC Press, Boca Raton, FL.
15. Krupp P and Barnes P (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99:3118-3121.
16. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
17. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, and Yunis EJ (1990) HLA-B38, Dr4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 47:945-948.
18. Liu ZC and Uetrecht JP (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 275:1476-1483.
19. Maggs JL, Williams D, Pirmohamed M, and Park BK (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 275:1463-1475.
20. Myers TG, Dietz EC, Anderson NL, Khairallah EA, Cohen SD, and Nelson SD (1995) A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its non-hepatotoxic regioisomer 3′-hydroxyacetanilide. Chem Res Toxicol 8:403-413.
21. National Halothane Study (1966) Summary of the National Halothane Study. JAMA 197:121-134.
22. Park BK, Pirmohamed M, and Kitteringham NR (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68: 385-424.
23. Pisciotta AV, Konnings SA, Ciesemier LL, Cronkite CE, and Lieberman JA (1992) Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med 119:254-266.
24. Pollmacher T, Hinze-Seich D, and Mullington J (1996) Effects of clozapine on plasma cytokines and soluble cytokine receptor levels. J Clin Psychopharmacol 16:403-409.
25. Pumford NR and Halmes NC (1997) Protein targets of xenobiotic reactive metabolites. Annu Rev Pharmacol Toxicol 37:91-117.
26. Tyndale RF, Bhave SV, Hoffmann E, Hoffmann PL, Tabakoff B, Tobin AJ, and Olsen RW (1997) Pentobarbital decreases the A receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation. J Pharmacol Exp Ther 283:350-357.
27. Uetrecht JP (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 24:299-366.
28. van der Poll T, van Deventer SJH, Hack EC, Wolbink GJ, Aarden LA, Buller HR, and ten Cate JW (1992) Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 79:693-698.
29. Veys PA, Wilkes S, Shah S, Noyelle R, and Hoffbrand AV (1992) Clinical experience of clozapine-induced neutropenia in the UK: laboratory investigation using liquid culture systems and immunofluorocytometry. Drug Safety 7:26-32.
30. Weigmann H and Hiemke C (1992) Determination of clozapine and its major metabolites in human serum using automated solid phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 583:209-216.
31. Williams D, Pirmohamed M, Naisbett D, Maggs J, and Park BK (1998) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375-1382.
32. Zeng J and Fenna RE (1992) X-ray crystal structure of canine myeloperoxidase at 3 A resolution. J Mol Biol 226:185-207.